Sign up to save your podcasts
Or
Share CANTOS: Dousing the Fire Within to Reduce CVD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
CANTOS: Dousing the Fire Within to Reduce CVD
Dr O’Donoghue discusses preliminary results from the CANTOS trial of canakinumab, a unique anti-inflammatory agent which represents a new pathway for treating cardiovascular disease.
View all episodes
By MedscapeDr O’Donoghue discusses preliminary results from the CANTOS trial of canakinumab, a unique anti-inflammatory agent which represents a new pathway for treating cardiovascular disease.